SCHEMBL18396759

SCHEMBL18396759

Cc1ccc(S(=O)(=O)OCC2CN(c3ccc(N4C5CC[C@@H]4CSC5)c(F)c3)C(=O)O2)cc1

nearest known ligand 0.45

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
MAOB P27338 11/20 0.45
MAOA P21397 5/20 0.43
GRM2 Q14416 2/20 0.40
LMNA P02545 1/20 0.40
PTGS1 P23219 1/20 0.40
CALML3 P27482 1/20 0.40
SDHA P31040 1/20 0.40
ALDH1A1 P00352 2/20 0.40
CYP3A4 P08684 2/20 0.40
CYP2D6 P10635 2/20 0.40
TSHR P16473 2/20 0.40
CYP2C9 P11712 1/20 0.40
CYP2C19 P33261 1/20 0.40
MAPT P10636 1/20 0.40
MAPK1 P28482 1/20 0.40
F10 P00742 4/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18396760 1.00 MAOB (0.45) MAOBMAOAGRM2LMNAPTGS1
SCHEMBL18396757 1.00 MAOB (0.45) MAOBMAOAGRM2LMNAPTGS1
SCHEMBL20296325 0.90 GRM2 (0.41) MAOBMAOAGRM2CALML3ALDH1A1
SCHEMBL18396729 0.90 GRM2 (0.41) MAOBMAOAGRM2CALML3ALDH1A1
SCHEMBL18408806 0.84 MAOB (0.54) MAOBMAOALMNAPTGS1CALML3
SCHEMBL20296415 0.84 MAOB (0.54) MAOBMAOALMNAPTGS1CALML3
SCHEMBL18410743 0.83 MAOB (0.47) MAOBMAOAGRM2LMNAPTGS1
SCHEMBL20295918 0.83 MAOB (0.47) MAOBMAOAGRM2LMNAPTGS1
SCHEMBL2464074 0.82 MAOB (0.64) MAOBMAOAGRM2LMNAPTGS1
SCHEMBL12317752 0.82 MAOB (0.64) MAOBMAOAGRM2LMNAPTGS1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11964949-B2 Substituted phenyloxazolidinones for antimicrobial therapy THE GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT, INC. (US) 2024-04-23 US disclosed
EP-3932917-A2 SUBSTITUTED PHENYLOXAZOLIDINONES FOR ANTIMICROBIAL THERAPY The Global Alliance for TB Drug Development, Inc. (US) 2022-01-05 EP disclosed
US-20200148651-A1 SUBSTITUTED PHENYLOXAZOLIDINONES FOR ANTIMICROBIAL THERAPY GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT INC (US) 2020-05-14 US disclosed
US-10550092-B2 Substituted phenyloxazolidinones for antimicrobial therapy THE GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT, INC. (US) 2020-02-04 US disclosed
US-20180179168-A1 SUBSTITUTED PHENYLOXAZOLIDINONES FOR ANTIMICROBIAL THERAPY THE GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT, INC. 2018-06-28 US disclosed
EP-3307268-A1 SUBSTITUTED PHENYLOXAZOLIDINONES FOR ANTIMICROBIAL THERAPY The Global Alliance for TB Drug Development Inc. (US) 2018-04-18 EP disclosed
WO-2017015106-A1 SUBSTITUTED PHENYLOXAZOLIDINONES FOR ANTIMICROBIAL THERAPY THE GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT, INC. (US) 2017-01-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11964949-B2 Substituted phenyloxazolidinones for antimicrobial therapy THPO, TBCD, OXA1L MAOB 1541/4885MAOA 2234/4885GRM2 4533/4885
US-20180179168-A1 SUBSTITUTED PHENYLOXAZOLIDINONES FOR ANTIMICROBIAL THERAPY THPO, TBCD, OXA1L MAOB 1541/4885MAOA 2234/4885GRM2 4533/4885
US-20200148651-A1 SUBSTITUTED PHENYLOXAZOLIDINONES FOR ANTIMICROBIAL THERAPY THPO, TBCD, OXA1L MAOB 1541/4885MAOA 2234/4885GRM2 4533/4885
US-10550092-B2 Substituted phenyloxazolidinones for antimicrobial therapy THPO, TBCD, OXA1L MAOB 1541/4885MAOA 2234/4885GRM2 4533/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.